Clinical Trial Update: Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing transarterial chemoembolization (TACE) to CyberKnife for recurrent hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Accuray Incorporated | Conditions: Recurrent Hepatocellular Carcinoma | Phase 3 | Status: WITHDRAWN